Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

408 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations.
Ciuffreda L, Del Bufalo D, Desideri M, Di Sanza C, Stoppacciaro A, Ricciardi MR, Chiaretti S, Tavolaro S, Benassi B, Bellacosa A, Foà R, Tafuri A, Cognetti F, Anichini A, Zupi G, Milella M. Ciuffreda L, et al. Among authors: tafuri a. Neoplasia. 2009 Aug;11(8):720-31. doi: 10.1593/neo.09398. Neoplasia. 2009. PMID: 19649202 Free PMC article.
The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms.
Ciuffreda L, Di Sanza C, Cesta Incani U, Eramo A, Desideri M, Biagioni F, Passeri D, Falcone I, Sette G, Bergamo P, Anichini A, Sabapathy K, McCubrey JA, Ricciardi MR, Tafuri A, Blandino G, Orlandi A, De Maria R, Cognetti F, Del Bufalo D, Milella M. Ciuffreda L, et al. Among authors: tafuri a. J Mol Med (Berl). 2012 Jun;90(6):667-79. doi: 10.1007/s00109-011-0844-1. Epub 2012 Jan 4. J Mol Med (Berl). 2012. PMID: 22215152
Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies.
Ricciardi MR, Scerpa MC, Bergamo P, Ciuffreda L, Petrucci MT, Chiaretti S, Tavolaro S, Mascolo MG, Abrams SL, Steelman LS, Tsao T, Marchetti A, Konopleva M, Del Bufalo D, Cognetti F, Foà R, Andreeff M, McCubrey JA, Tafuri A, Milella M. Ricciardi MR, et al. Among authors: tafuri a. J Mol Med (Berl). 2012 Oct;90(10):1133-44. doi: 10.1007/s00109-012-0886-z. Epub 2012 Mar 8. J Mol Med (Berl). 2012. PMID: 22399013
MEK blockade converts AML differentiating response to retinoids into extensive apoptosis.
Milella M, Konopleva M, Precupanu CM, Tabe Y, Ricciardi MR, Gregorj C, Collins SJ, Carter BZ, D'Angelo C, Petrucci MT, Foà R, Cognetti F, Tafuri A, Andreeff M. Milella M, et al. Among authors: tafuri a. Blood. 2007 Mar 1;109(5):2121-9. doi: 10.1182/blood-2006-05-024679. Epub 2006 Oct 31. Blood. 2007. PMID: 17077328 Free article.
Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies.
Tortora G, Bianco R, Daniele G, Ciardiello F, McCubrey JA, Ricciardi MR, Ciuffreda L, Cognetti F, Tafuri A, Milella M. Tortora G, et al. Among authors: tafuri a. Drug Resist Updat. 2007 Jun;10(3):81-100. doi: 10.1016/j.drup.2007.03.003. Epub 2007 May 7. Drug Resist Updat. 2007. PMID: 17482503 Free PMC article. Review.
The tissue inhibitor of metalloproteinases 1 increases the clonogenic efficiency of human hematopoietic progenitor cells through CD63/PI3K/Akt signaling.
Rossi L, Forte D, Migliardi G, Salvestrini V, Buzzi M, Ricciardi MR, Licchetta R, Tafuri A, Bicciato S, Cavo M, Catani L, Lemoli RM, Curti A. Rossi L, et al. Among authors: tafuri a. Exp Hematol. 2015 Nov;43(11):974-985.e1. doi: 10.1016/j.exphem.2015.07.003. Epub 2015 Jul 23. Exp Hematol. 2015. PMID: 26213230 Free article.
408 results